Artivion (AORT) Competitors

Soleno Therapeutics (NASDAQ:SLNO) and Artivion (NYSE:AORT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.

Which has stronger valuation and earnings, SLNO or AORT?

Artivion has higher revenue and earnings than Soleno Therapeutics. Artivion is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	N/A	N/A	-$38.99M	-$4.26	-17.51
Artivion	$388.54M	2.59	-$30.69M	-$0.31	-76.02

Does the media prefer SLNO or AORT?

In the previous week, Soleno Therapeutics had 10 more articles in the media than Artivion. MarketBeat recorded 15 mentions for Soleno Therapeutics and 5 mentions for Artivion. Artivion's average media sentiment score of 1.46 beat Soleno Therapeutics' score of 1.11 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, SLNO or AORT?

Soleno Therapeutics has a beta of -2.29, suggesting that its stock price is 329% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.

Does the MarketBeat Community prefer SLNO or AORT?

Soleno Therapeutics received 294 more outperform votes than Artivion when rated by MarketBeat users. However, 81.82% of users gave Artivion an outperform vote while only 72.62% of users gave Soleno Therapeutics an outperform vote.

Company	Underperform	Outperform
Soleno Therapeutics	Outperform Votes 321 72.62%	Underperform Votes 121 27.38%
Artivion	Outperform Votes 27 81.82%	Underperform Votes 6 18.18%

Do analysts rate SLNO or AORT?

Soleno Therapeutics presently has a consensus target price of $104.67, indicating a potential upside of 40.32%. Artivion has a consensus target price of $31.40, indicating a potential upside of 33.25%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Soleno Therapeutics is more favorable than Artivion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Artivion	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals believe in SLNO or AORT?

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by company insiders. Comparatively, 7.6% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is SLNO or AORT more profitable?

Soleno Therapeutics has a net margin of 0.00% compared to Artivion's net margin of -0.22%. Artivion's return on equity of 5.15% beat Soleno Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	N/A	-61.99%	-55.21%
Artivion	-0.22%	5.15%	1.91%

Summary

Soleno Therapeutics beats Artivion on 10 of the 18 factors compared between the two stocks.